The Big Data Institute (BDI) have recently announced new research alliances with Novartis and Sensyne Health; a five year collaboration with Novatis to establish a world-leading research alliance that will improve drug development by making it more efficient and more targeted. And a 3 year alliance with Sensyne Health to advance the analysis and interpretation of NHS datasets
Funding will be provided to the University of Oxford through the Government’s Industrial Strategy Challenge Fund by as part of a £50 million investment to establish a network of digital pathology, imaging and AI centres, to drive innovation in the use of AI for improved diagnosis and delivery of precision treatments. Oxford is to be home to one of the five new technology centres across the country, and is also a collaborator in two of the other centres, with local activities integrated within the Big Data Institute
BRCA1 deficiencies cause breast and ovarian cancer, rendering tumours hypersensitive to PARP inhibitors. Patient treatment can become ineffective due to emerging resistance mechanisms. Ross Chapman’s team at the Welcome Centre has uncovered a protein complex termed Shieldin that acts with 53BP1 to limit end resection at DNA double-strand breaks, which confers resistance to cancer treatment.
Ioannis Psallidas (Respiratory Medicine) and colleagues including members of the Target Discovery Institute (TDI) (Benedikt Kessler / Roman Fischer) have developed a score that predicts risk of death for a common metastasis of patients with malignant pleural effusion. Four proteins with a significant role in survival have been discovered, leading the road for new disease treatment. The PROMISE study results have been published in Lancet Oncology.
The FORMA/Oxford collaboration brings together Oxford’s expertise in disease molecular pathology and Ubiquitin biology, (including through the Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI), the Target Discovery Institute (TDI) and the Oxford Parkinson’s Disease Centre (OPDC)), and FORMA’s deep expertise in small molecule drug design and development.
Researchers in Ireland, the UK and US have discovered a new metabolic process in the body that can switch off inflammation. “itaconate” – a molecule derived from glucose – “acts as a powerful off switch for macrophages”, thereby reducing inflammation. The discovery published in Nature offers more effective treatment of inflammatory diseases such as arthritis, inflammatory bowel disease and heart disease. Roman Fischer and Benedikt Kessler from the Target Discovery Institute (TDI) participated in this study.
A free one day symposium, to be held on 20 April 2018, Medical Sciences Training Centre, Oxford and organised by the Postdoctoral Training Fellows at MRC Harwell Institute. The theme is the influence of genetics and genetic regulation in modelling human disease – from molecular through cellular to whole animal level and encompassing developmental, environmental and behavioural interactions. Register here to attend for free.
Health Data Research UK is awarding £30 million funding to six sites across the UK, including the University of Oxford, to address challenging healthcare issues through use of data science. Professor Martin Landray, Director of the Health Data Research UK Oxford site said: 'We are delighted that the Big Data Institute at University of Oxford will play a major part in Health Data Research UK. This exciting endeavour brings new opportunities to understand the causes of disease and to develop new treatments with substantial benefits for patients and public health.'
Congratulations to Professor Chas Bountra, Professor of Translational Medicine at the Nuffield Department of Medicine, who has been appointed OBE for services to Translational Medical Research in the New Year's Honours List 2018. Congratulations also to
Dr Jake Dunning, Honorary Visiting Research Fellow in Tropical Medicine (ERGO) who has been appointed MBE for services to Clinical Research.